• Space invaders

    Next-generation cell and gene therapies are spurring demand for manufacturing space in key life sciences clusters

  • The rise of patient 2.0

    Janssen’s Emily Bone talks about modern patient engagement evolution and why it is the driving force for a brave new era

News

View all

Web Exclusives

View all
Thumbnail image for Group therapy

Group therapy

Sharon King talks about her experience of bringing up a child with Batten disease and the team approach needed to develop gene therapies for rare diseases

Thumbnail image for Vision for diversity

Vision for diversity

As we enter a new era of inclusivity are we really doing enough to improve health equity in clinical trials?

Thumbnail image for Whole new world

Whole new world

Modern pharma is increasingly about the applying real-world evidence to gene therapies

Thumbnail image for Stark similarities

Stark similarities

How biosimilars support sustainability throughout global healthcare systems and deliver the building blocks for vital healthcare

Thumbnail image for Be patient

Be patient

Awareness raising is key to boosting patient involvement and engendering trust

Thumbnail image for Back to life

Back to life

The 2022 International Clinical Researcher of the Year awards recognised our industry’s incredible array of talent – in person!

Thumbnail image for Our imagination

Our imagination

One year on from the launch of the Government’s Life Sciences Vision there is a unique opportunity for the UK to become a genuine industry superpower.

Thumbnail image for A quiet revolution?

A quiet revolution?

Though barely mentioned in the NHS reform debate, some major changes to Specialised Commissioning are on the way

Thumbnail image for Tomorrow’s world

Tomorrow’s world

As a new era for pharma begins to unfold life sciences pioneers are changing their environments

Thought Leadership

View all
Thumbnail image for Orphan Drug Development

Orphan Drug Development

Rare diseases (RDs) or orphan diseases, by definition, are conditions that affect a small number of individuals. The exact number of RDs is unknown, but it is estimated to be approximately 6000-8000.

Thumbnail image for Native advertising is exploding across healthcare, have you jumped in?

Native advertising is exploding across healthcare, have you jumped in?

In the last 2 years, and accelerated by Covid, native advertising has exploded across healthcare for DTC and HCP marketing. Native ads have been adopted by all healthcare industries including pharma, device, health systems, retailers, pharmacies, payers, and the gamut of regional service providers. But there are still a handful of advertiser holdouts, and they are missing out on highly engaged audiences.

Webinars

View all

Diversity in Pharma: The Impact of COVID-19 on DE&I

Thursday, 23 June 2022 - 3:00 pm

COVID-19 has had a huge impact on how we all think and act. Our working environments may look very different now to the way they did pre-pandemic, and not all the changes have been negative.

Andrés López Castaño, Tricia Lucas-Clarke, Noor Shaker, Sandra Van de Cauter, Marsha N. Ganthier

FREE | REGISTER NOW

Patient Perspectives to Improve Retention with eConsent

Tuesday, 22 February 2022 - 4:00 pm

With Tufts reporting that the average number of patient dropouts for clinical trials remains near 30%, it is clear that there is still much to be done towards improving retention¹.

Andrew Mackinnon, Digital Trial Operations Lead, Medable

FREE | ATTEND

Focusing on Patient-centricity for the Future of Pharma

Wednesday, 21 July 2021 - 2:00 pm

In healthcare, the patient voice is arguably the most important. Services and care work best when a person’s needs are fully met and they feel heard, respected and valued.

Mark Doyle, co-founder of The Method and creator of A Life in a Day

FREE | ATTEND

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download